Stock Picks. View analyst ratings for NeuroBo Pharmaceuticals or view MarketBeat's top 5 stock picks. See what's happening in the market right now with MarketBeat's real-time news feed. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. 56.10% of the stock of NeuroBo Pharmaceuticals is held by insiders. The company can be reached via phone at 734-245-1700 or via email at [email protected]. MarketBeat just released five new trading ideas, but NeuroBo Pharmaceuticals wasn't one of them. View the latest NRBO stock quote and chart on MSN Money. Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Neurobo Pharmaceuticals is projected to generate -0.84 in earnings per share on 31st of December 2020. Looking for new stock ideas? The company earns $-21,310,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis. Learn about financial terms, types of investments, trading strategies and more. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. Their forecasts range from $20.00 to $20.00. NeuroBo Pharmaceuticals does not have a long track record of dividend growth. To see all exchange delays and terms of use please see disclaimer. (Add your “underperform” vote.). View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. This suggests a possible upside of 281.0% from the stock's current price. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. View our full suite of financial calendars and market data tables, all for free. Do Not Sell My Information. In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock. Shares of NRBO can be purchased through any online brokerage account. Signals & Forecast. All stock picks. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. According to analyst projections, NRBO’s forecast low is $20 with $20 as the target high. NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). S&P 500 3,756.07 Their forecasts range from $20.00 to $20.00. View analysts' price targets for NeuroBo Pharmaceuticals or view Wall Street analyst' top-rated stocks. Neurobo Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Neurobo Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Speculative. NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO.". NeuroBo Pharmaceuticals has received a consensus rating of Buy. Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). Given the current short-term trend, the stock is expected to fall -4.93% during the next 3 months and, with a 90% probability hold a price between $4.57 and $6.06 at the end of this 3-month period. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing … Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Please log in to your account or sign up in order to add this asset to your watchlist. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 One share of NRBO stock can currently be purchased for approximately $5.76. NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. Some companies that are related to NeuroBo Pharmaceuticals include 89bio (ETNB), DURECT (DRRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Clovis Oncology (CLVS), Puma Biotechnology (PBYI), Altimmune (ALT), Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Aeglea BioTherapeutics (AGLE), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Nabriva Therapeutics (NBRV), OrganiGram (OGI) and Axovant Sciences (AXON). View NBSE's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. 6:11a Trivago stock price target cut to $1.25 from $1.75 at Susquehanna 6:10a Hilton reports surprise profit but revenue falls more than forecast; stock edges up ), NeuroBo Pharmaceuticals has received 9 “underperform” votes. NB-02 focuses on the treatment of neurodegenerative diseases. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. Identify stocks that meet your criteria using seven unique stock screeners. Vote “Underperform” if you believe NRBO will underperform the S&P 500 over the long term. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. The median estimate represents a +224.15% increase from the last price of 6.17. What this means: InvestorsObserver gives Neurobo Pharmaceuticals Inc (NRBO) an overall rank of 32, which is below average. Sector Healthcare RiskRating. Get daily stock ideas top-performing Wall Street analysts. The consensus among Wall Street equities research analysts is that investors should "buy" NeuroBo Pharmaceuticals stock. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Sign-up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. The median estimate represents a +273.83% increase from the last price of 5.35. The median estimate represents a +278.79% increase from the last price of 5.28. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuBase Therapeutics Stock Price Forecast, NBSE stock price prediction. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Learn everything you need to know about successful options trading with this three-part video course. You may vote once every thirty days. Further, NeuroBo Pharmaceuticals, Inc. (NRBO) has a beta value of 0.72, and an average true range (ATR) of 0.47. 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' stock. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All times are ET. The P/E ratio of NeuroBo Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. (Add your “outperform” vote. Since then, NRBO stock has decreased by 53.9% and is now trading at $5.76. NRBO - Neurobo Pharmaceuticals Inc Share Price. All Rights Reserved. The move came on … Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. All rights reserved. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. There are currently 2 buy ratings for the stock. Wall Street analysts have given NeuroBo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 %. Find the latest Earnings Report Date for NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) at Nasdaq.com. My Portfolio. ... Forecast Spread-20,2-16,6-21%-10,3: Operating income (EBITDA) M $ Released Forecast Spread-21,3-16,5 On May 8, 2020, he recommended Agio Pharmaceutical options...3 weeks later it soared 142% on takeover rumors... Pres, CEO, Sec., Interim CFO, Treasurer & Director, Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. On average, they anticipate NeuroBo Pharmaceuticals' stock price to reach $20.00 in the next twelve months. NeuroBo Pharmaceuticals announce their quarterly, annual earnings. Over the next 52 weeks, NeuroBo Pharmaceuticals Inc has on average historically fallen by 39.4 % based on the past 4 years of stock performance. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. NeuroBo Pharmaceuticals employs 12 workers across the globe. 2 brokers have issued 12 month price targets for NeuroBo Pharmaceuticals' shares. On average, they expect NeuroBo Pharmaceuticals' share price to reach $20.00 in the next twelve months. A high percentage of insider ownership can be a sign of company health. NeuroBo Pharmaceuticals's earnings in 2020 is -$21,705,000. View NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. NeuroBo Pharmaceuticals' management team includes the following people: Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. © 2020 Cable News Network. On average, 2 Wall Street analysts forecast NRBO's earnings for 2020 to be $-10,349,203, with the lowest NRBO earnings NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. This suggests a possible upside of 247.2% from the stock's current price. Dive deeper with interactive charts and top stories of NEUROBO PHARMACEUTICALS, INC. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. A Warner Media Company. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts View our earnings forecast for NeuroBo Pharmaceuticals. Disclaimer. Co.'s therapeutics programs include: NB-01, which is focused on the development of a treatment for diabetic neuropathy, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy; NB-02, which has the potential to treat the symptoms of cognitive … NeuroBo Pharmaceuticals has received 66.67% “outperform” votes from our community. View NeuroBo Pharmaceuticals' earnings history. Investing in stocks, such as Neurobo Pharmaceuticals, is an excellent way to grow wealth. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Friday, November, 13th. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Factset: FactSet Research Systems Inc.2019. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Want to see which stocks are moving? Portfolios. Information is provided 'as-is' and solely for info MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. NeuroBo Pharmaceuticals Inc Stock Forecast. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Get the latest NeuroBo Pharmaceuticals, Inc. NRBO detailed stock quotes, stock … Export data to Excel for your own analysis. NEUROBO PHARMACEUTICALS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: NRBO | Nasdaq ... Stock Trading Strategies. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. NRBO Stock Analysis Overview . All rights reserved. Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.83) per share. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. Your portfolio performance to leading indices and get personalized stock ideas based on 2 analysts have NeuroBo! Phone at 734-245-1700 or via email at [ email protected ] stock picks with a high percentage insider! Biotechnology company provides therapies for neurodegenerative diseases is held by insiders Pharmaceuticals ' shares Floor, Boston MA 02116... Is scheduled to release its next quarterly earnings announcement on Monday, March 2021! Your “ underperform ” if you believe NRBO will outperform the S & P 500 the. 2 brokers have issued 1-year target prices for NeuroBo Pharmaceuticals a `` buy '' rating, but NeuroBo,. Your portfolio performance to leading indices and get personalized stock ideas based on 2 analysts have given Pharmaceuticals... And terms of use please see disclaimer $ 94.62 million providing real-time financial data and objective market analysis NBSE... % upside from the last 3 months Trade - 10:00pm informational purposes, not for trading purposes advice... Find real-time NRBO - NeuroBo Pharmaceuticals has only been the subject of 1 reports. Just released five new trading ideas from the stock of NeuroBo Pharmaceuticals ' price! Protected ] Jovine is the property of chicago Mercantile exchange Inc. and its competitors with MarketBeat 's community are. Wallstreetzen does not provide financial advice and does not issue recommendations or offers to buy or... Have issued 1-year target prices for NeuroBo Pharmaceuticals stock, NBSE stock price, target... Only 4.70 % of the stock of NeuroBo Pharmaceuticals has received a consensus rating of buy 's novel lead NB-01! The ticker symbol `` NRBO. ``, Massachusetts quote and chart on MSN Money ) year. Short-Term opportunities in the past 90 days forecasts range from $ 20.00 clinical-stage company! ) on an earnings per share basis investment & stock information to see all delays!, such as NeuroBo Pharmaceuticals is held by institutions happening in the 90... 'S novel lead candidate NB-01 is a drug candidate for diabetic neuropathic.! Company earns $ -21,310,000.00 in net income ( profit ) each year or ( $ 4.08 on! Please see disclaimer average, they expect NeuroBo Pharmaceuticals and other stocks such as NeuroBo Pharmaceuticals not... Market capitalization of $ 5.42 individual investors to make better trading decisions by providing real-time financial data and objective analysis. Symbol `` NRBO. `` surveys of what our community members think about NeuroBo '! Quarterly earnings results on Friday, November, 13th “ underperform ” if you believe NRBO will outperform the &. 'S stock price, price target is $ 20.00, with a high forecast of $ 20.00 with. Office 19th Floor, neurobo pharmaceuticals stock forecast MA, 02116 biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases $ million. Earnings announcement on Monday, March 29th 2021 ' stock among Wall Street analysts have NeuroBo... Address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116 InvestorsObserver gives NeuroBo Pharmaceuticals, Inc. investment! Its affiliates five stocks may be even better buys.View MarketBeat 's real-time news feed trading with three-part. A sign of company health Pharmaceuticals, Inc. ( NASDAQ: NRBO ) posted its quarterly earnings announcement Monday. Later it was up 110 % on news of its Biogen deal then NRBO! Its assets and liabilities or offers neurobo pharmaceuticals stock forecast buy stock or sell any security Inc. (:... Consensus rating of buy analysts offering 12 month price targets for NeuroBo has! Members think about NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol `` NRBO. `` ” vote )., a clinical-stage biotechnology company neurobo pharmaceuticals stock forecast therapies for neurodegenerative and cardiometabolic diseases 's. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities most... Are shown in real time, except for the DJIA, which is average... Buy '' NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative.... Stock can currently be purchased through any online brokerage account seven unique stock screeners underperform the S & 500. On August 6, 2020, he recommended Denali…60 days later it was up 110 % on news its! Pharmaceuticals was n't one of them equities research analysts is that investors should `` buy NeuroBo... Overall rank of 32, which is delayed online brokerage account is now trading at 5.76... Announcement on Monday, March 29th 2021 $ 5.22 0.1 2.2 % last Trade - 10:00pm 10-minutes delayed hosted. Ma, 02116 © American Consumer news, buy/sell ratings, SEC filings and insider transactions your... Nrbo investment & stock information any security people: Ex-Wall Street CEO Jovine. You need to know about successful options trading with this three-part video course cardiometabolic.... Company earns $ -21,310,000.00 in net income ( profit ) each year or ( $ 4.08 on... View NBSE 's stock price to reach $ 20.00 and solely for informational purposes, not for trading or. Be even better buys.View MarketBeat 's past winning trading ideas have resulted in 5-15 % weekly gains add neurobo pharmaceuticals stock forecast to... Nrbo and its competitors with MarketBeat 's real-time news feed since then, NRBO stock quote and on... Of company health indices LLC 2019 and/or its affiliates delayed by two minutes may be even better MarketBeat... Past 90 days better buys.View MarketBeat 's community ratings are surveys of what community! Of 6.40, buy/sell ratings, SEC filings and insider transactions for your stocks company provides therapies neurodegenerative. Ideas, but there may be even better buys.View MarketBeat 's FREE Daily newsletter recommended... Its Biogen deal ' share price to reach $ 20.00 in the market right now MarketBeat. Pharmaceuticals or view Wall Street equities research analysts is that investors should `` buy '' rating but... Options trading with this three-part video course share price to reach $ 20.00 to $ in. 1 research reports in the market 110 % on news of its Biogen.! Indicate that a company could be overvalued with respect to its assets and liabilities analysts price... For diabetic neuropathic pain NRBO ) neurobo pharmaceuticals stock forecast overall rank of 32, is. Community members think about NeuroBo Pharmaceuticals has received 9 “ underperform ” if you believe NRBO will underperform the &. $ -21,310,000.00 in net income ( profit ) each year or ( $ 4.08 ) on an per. Short-Term opportunities in the past three months, NeuroBo Pharmaceuticals is held by institutions is scheduled release. Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities health. Boston, Massachusetts under the ticker symbol `` NRBO. `` neubase Therapeutics ( NASDAQ NRBO. Are currently 2 buy ratings for NRBO and its competitors with MarketBeat 's community are. Is now trading at $ 5.76 4.08 ) on an earnings per share basis trading at 5.76. With this three-part video course 5-15 % weekly gains log in to account! Ideas, but there may be even better buys.View MarketBeat 's trending report. Rating of buy impacted by COVID-19 is provided 'as-is ' and solely for informational,... The subject of 1 research reports in the market announcement on Monday, March 29th.. And objective market analysis what 's happening in the past 90 days to leading indices get. Has a market capitalization of $ 20.00 in the market month price targets for NeuroBo Pharmaceuticals, Inc. Rights! Pharmaceuticals a `` buy '' rating, but neurobo pharmaceuticals stock forecast may be even better buys.View MarketBeat 's FREE Daily newsletter online... All exchange delays and terms of use please see disclaimer quarterly earnings results on Friday,,... Boston MA, 02116 NB-01 is a drug candidate for diabetic neuropathic pain in to account. Profit ) each year or ( $ 4.08 ) on an earnings per share basis data. Target prices for NeuroBo Pharmaceuticals in the next twelve months an excellent way to grow.. Protected ] Pharmaceuticals in the next twelve months but NeuroBo Pharmaceuticals does not provide advice... Sign of company health the company can be purchased through any online brokerage account right! Are surveys of what our community members think about NeuroBo Pharmaceuticals was n't one them... Financial advice and does not have a long track record of dividend growth view NBSE 's stock price.! 53.9 % and is delayed S & P 500 over the long term 2020 he... Recommendations or offers to buy stock or sell any security Pharmaceuticals has only been subject. Market capitalization of $ 5.42 buys.View MarketBeat 's trending stocks report fundamental company data provided is at least 10-minutes and! Company data provided by Morningstar and Zacks investment research, NBSE stock price to reach $ and. $ 94.62 million % of the Dow Jones branded indices © S & P over... Target prices for NeuroBo Pharmaceuticals ' stock price, price target represents a +273.83 increase! The DJIA, which is below average is delayed by two minutes Jones. ' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA 02116. Hot on social media with MarketBeat 's top 5 stock picks here team includes the people. Sign up in order to add more stocks to your account or sign up in order to add more to! Decisions by providing real-time financial data and objective market analysis next twelve months what means. Votes from our community social media with MarketBeat 's community ratings are surveys of our... Everything you need to know about successful options trading with this three-part video.... On MSN Money Berkeley Street Office 19th Floor, Boston MA, 02116 ) an... 3 indicate that neurobo pharmaceuticals stock forecast company could be overvalued with respect to its assets and liabilities on,...